June 10 (Reuters) - Unicycive Therapeutics Inc UNCY.O:
UNICYCIVE PROVIDES UPDATE ON NEW DRUG APPLICATION FOR OXYLANTHANUM CARBONATE TO TREAT HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
UNICYCIVE THERAPEUTICS INC - FDA FINAL DECISION ON OLC NDA EXPECTED BY JUNE 28, 2025
UNICYCIVE THERAPEUTICS INC - FDA IDENTIFIES DEFICIENCIES AT THIRD-PARTY MANUFACTURING VENDOR
UNICYCIVE THERAPEUTICS INC - FDA IDENTIFIES CGMP COMPLIANCE DEFICIENCIES AT THIRD-PARTY VENDOR
Source text: ID:nGNXSJW8K
Further company coverage: UNCY.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.